Vitamin K2 TAKEOVER Trial: Neuromuscular Recovery Shortens in Adults 65+

The randomized TAKEOVER trial evaluating vitamin K2 (MK-7) effects on neuromuscular function was published in Medicine & Science in Sports & Exercise (DOI 10.1249/MSS.0000000000003901). The differential response between two age cohorts (18-40 vs 65+) is the key finding.

TAKEOVER trial design

12 weeks, randomized, double-blind, placebo-controlled. The K2VITAL ingredient (a standardized MK-7 from Balchem) was used. Researchers compared strength, soreness, inflammation markers, and neuromuscular function across the two cohorts.

Full-cohort primary endpoint results. No difference vs placebo on strength, soreness, or exercise-induced inflammation. The simple marketing message “vitamin K2 helps recovery” is not supported.

Shorter EMD in adults 65+

The interesting finding came from age-stratified analysis. In the 65+ cohort, electromechanical delay (EMD) after exercise shortened in the K2 group.

EMD is the time between when a nerve signal reaches the muscle and when actual force is generated. Shorter EMD means faster neuromuscular response. EMD typically lengthens with age, and this is associated with fall risk.

K2 supplementation shortening EMD in adults 65+ signals improved neuromuscular recovery speed. No difference was observed in the 18-40 cohort.

Gas6, a vitamin K-dependent neuroprotective protein

The proposed mechanism is Gas6 (Growth Arrest-Specific 6), a vitamin K-dependent protein involved in nervous system growth and protection. Without sufficient vitamin K, Gas6 carboxylation is incomplete and function declines.

Vitamin K status tends to decline with age, and Gas6’s neuromuscular junction protection weakens with it. K2 supplementation may restore this mechanism, shortening EMD.

This doesn’t mean K2 is meaningless for adults 18-40

The trial measured only short-term recovery effects (strength, soreness, inflammation). Vitamin K2’s best-known effects, bone density maintenance and arterial calcification inhibition, play out over years. A 12-week trial cannot evaluate them.

The standard recommended dose for K2 is 90-180 μg/day (MK-7 form). Clinical trials typically use 100-200 μg/day. The exact trial dose is in the published paper.

Implication: precision in age-targeted supplements

Two implications.

First, the “K2 is good for everyone” generalization weakens. The population showing measurable effect narrows to 65+. Younger adults may still gain bone and vascular long-term benefit but should not expect short-term recovery effects.

Second, age-related neuromuscular decline emerges as a new target for vitamin K2. A new option for falls, sarcopenia, and balance.

Combined with this quarter’s senolytic data (Mayo Clinic D+Q), NMN/NR/NAD+ boosters, and GLP-1 aesthetic behavior surveys, a supplement matrix differentiated by age mechanism is taking shape. Bone is calcium + D3 + K2. Mitochondria is NMN/NR/Urolithin A. Senescent cells is D+Q. The shift from a single multivitamin to mechanism-specific precision supplementation.

Daily guide

For adults 65+ starting exercise or noticing balance decline, vitamin K2 (MK-7) 100-180 μg/day is worth considering. Important caveat: if taking warfarin (Coumadin) or other anticoagulants, consult a doctor first. Vitamin K can weaken anticoagulant effects.

Food sources include natto (K2 rich), cheese, egg yolks, butter, and goose liver. Reaching clinical doses through food alone is difficult.